Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NRW3
UPID:
ABC3C_HUMAN
Alternative names:
APOBEC1-like; Phorbolin I
Alternative UPACC:
Q9NRW3; B2R884; Q5JZ92; Q7Z2N7; Q96F12
Background:
The DNA dC->dU-editing enzyme APOBEC-3C, also known as APOBEC1-like or Phorbolin I, plays a pivotal role in the cellular defense mechanism against retrovirus replication and retrotransposon mobility. It achieves this through both deaminase-dependent and -independent pathways, effectively inducing G-to-A hypermutations in viral DNA and exerting antiretroviral effects. This enzyme selectively targets single-stranded DNA, sparing double-stranded DNA and RNA, and showcases antiviral activity against a range of viruses including SIV, HBV, HHV-1, and EBV.
Therapeutic significance:
Understanding the role of DNA dC->dU-editing enzyme APOBEC-3C could open doors to potential therapeutic strategies, particularly in the context of viral infections and the regulation of gene expression through active DNA demethylation.